Get the Stockscreener App
1.25
3.31%
0.04
Renovorx Inc stock is traded at $1.25, with a volume of 6,572.
It is up +3.31% in the last 24 hours and down -8.09% over the past month.
RenovoRx Inc is a clinical-stage biopharmaceutical company developing proprietary targeted combination therapies for high unmet medical need with a goal to improve therapeutic outcomes for cancer patients undergoing treatment. RenovoRx's patented Trans-Arterial Micro-Perfusion therapy platform is designed to ensure precise therapeutic delivery to directly target the tumor while potentially minimizing a therapy's toxicities versus systemic intravenous therapy.
See More
Previous Close:
$1.21
Open:
$1.22
24h Volume:
6,572
Relative Volume:
0.04
Market Cap:
$45.72M
Revenue:
-
Net Income/Loss:
$-9.16M
P/E Ratio:
-2.193
EPS:
-0.57
Net Cash Flow:
$-8.75M
1W Performance:
+0.00%
1M Performance:
-8.09%
6M Performance:
-7.41%
1Y Performance:
+1.63%
1-Day Range:
$1.22
$1.25
1-Week Range:
$1.20
$1.275
52-Week Range:
$0.75
$1.6899
Renovorx Inc Stock (RNXT) Company Profile
Name
Renovorx Inc
Sector
Industry
Phone
408-800-2649
Address
2570 W. EL CAMINO REAL, STE. 320,, MOUNTAIN VIEW
Compare RNXT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RNXT
Renovorx Inc
|
1.25 | 45.35M | 0 | -9.16M | -8.75M | -0.57 |
|
VRTX
Vertex Pharmaceuticals Inc
|
464.92 | 118.67B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
571.64 | 59.23B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
408.98 | 52.67B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
677.23 | 41.24B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
301.30 | 32.36B | 3.81B | -644.79M | -669.77M | -6.24 |
Renovorx Inc Stock (RNXT) Latest News
Is RenovoRx Inc. a growth stock or a value stockBreakthrough capital growth - jammulinksnews.com
What analysts say about RenovoRx Inc. stockUnlock powerful trading alerts for success - jammulinksnews.com
What is RenovoRx Inc. company’s growth strategyHigh-octane financial growth - jammulinksnews.com
Published on: 2025-08-04 04:04:54 - jammulinksnews.com
How volatile is RenovoRx Inc. stock compared to the marketGet timely market insights for better trades - jammulinksnews.com
What are analysts’ price targets for RenovoRx Inc. in the next 12 monthsUnlock steady growth with low-risk stocks - jammulinksnews.com
How does RenovoRx Inc. generate profit in a changing economyAccelerated profit realization - jammulinksnews.com
What are RenovoRx Inc. company’s key revenue driversGet daily expert analysis on top stocks - jammulinksnews.com
What are the technical indicators suggesting about RenovoRx Inc.Breakneck growth rates - jammulinksnews.com
Is RenovoRx Inc. stock overvalued or undervaluedAchieve rapid portfolio appreciation today - jammulinksnews.com
What makes RenovoRx Inc. stock price move sharplyAchieve superior returns through strategic trading - jammulinksnews.com
What drives RenovoRx Inc. stock priceOutstanding stock performance - jammulinksnews.com
When is RenovoRx Inc. stock expected to show significant growthUnlock market-leading stock analysis - jammulinksnews.com
Should I hold or sell RenovoRx Inc. stock in 2025Outstanding stock performance - jammulinksnews.com
What catalysts could drive RenovoRx Inc. stock higher in 2025Accelerated investment success - jammulinksnews.com
What institutional investors are buying RenovoRx Inc. stockUnlock powerful trading alerts for success - jammulinksnews.com
RenovoRx (NASDAQ:RNXT) Rating Lowered to Sell at Wall Street Zen - Defense World
Exit strategy if you’re trapped in RenovoRx Inc.Swing Trade Entry and Exit Point Analysis - Newser
Will RenovoRx Inc. price bounce be sustainableFree Capital Growth With Controlled Risk Picks - Newser
Why RenovoRx Inc. stock attracts strong analyst attentionDaily Market Momentum and Pressure Analysis - Newser
Will RenovoRx Inc. stock recover after recent dropMinimal Risk Growth Investment Opportunity Analysis - Newser
Can you recover from losses in RenovoRx Inc.Short-Term Stock Trend Forecast Guide - Newser
How RenovoRx Inc. stock performs during market volatilityPattern Breakout Tracker with Screener Tools - Newser
Earnings Preview For RenovoRx - 富途牛牛
Can swing trading help recover from RenovoRx Inc. lossesDaily Equity Signal Strength Summary Report - Newser
RenovoRx Inc. stock prediction for this weekFree Short Term High Yield Stock Tips - Newser
New Product Launches: Will They Boost RenovoRx Inc. Stock in 2025Fast Entry High Potential Stock Alerts Triggered - metal.it
Heatmap analysis for RenovoRx Inc. and competitorsBuy Signal System Based on Price Action - Newser
Moving Average Trends for RenovoRx Inc. Stock: What They IndicateShort-Term Stock Trend Forecast Guide - Newser
Ellis Martin Report: Redefining Cancer TreatmentRenovoRx, Inc. (NASDAQ:RNXT) CEO Shaun Bagai on Targeted Pancreatic Therapy - ABN Newswire
RenovoRx launches multi-centre post-marketing registry study - European Pharmaceutical Manufacturer
RenovoRx Inc. Moves Into Bullish Territory Based on MACDLow Risk High Return Opportunities Identified - metal.it
Is this a good reentry point in RenovoRx Inc.Oversold Stock Bounce Playbook Generator - Newser
Pancreatic Ductal Adenocarcinoma Clinical Trials, Companies, Therapeutic Assessment, Therapies, Treatment Algorithm, Pipeline Analysis | Cardiff Oncology, XOMA, Alphamab, Cantargia, RenovoRx, Syntrix - Barchart.com
RenovoRx Launches Multi-Center Post-Marketing Registry Study to Evaluate Cancer Treatment Delivered by RenovoCath® Device to Solid Tumors - BioSpace
RenovoRx launches post-marketing study to advance real-world use of RenovoCath Device - Medical Economics
RenovoRx to launch post-marketing registry study for cancer device By Investing.com - Investing.com Nigeria
Renovorx Inc Stock (RNXT) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.54%
0.05%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):